Group 1 (n = 17) | Group 2 (n = 10) | Group 3 (n = 17) | P value | |
---|---|---|---|---|
Age, y | 54.8 ± 11.9 | 59.2 ± 10.2 | 50.9 ± 12.2 | 0.14 |
Male, n (%) | 13 (76%) | 7 (70%) | 14 (82%) | 0.18 |
BSA (m2) | 1.9 ± 0.2 | 1.8 ± 0.2 | 1.8 ± 0.1 | 0.32 |
EuroSCORE 2* | 0.98% | 0.96% | 0.95% | 0.45 |
LVEF | 60.4 ± 6.4 | 58.2 ± 4.1 | 64.5 ± 4.7 | 0.32 |
TAPSE (mm) | 24.5 ± 4.8 | 27.4 ± 5.3 | 23.5 ± 4 | 0.17 |
SPAP (mmHg) | 33.9 ± 4.8 | 32.3 ± 5.1 | 34.9 ± 2.7 | 0.83 |
RVEF (3D) | 62.2 ± 8.9 | 60.5 ± 8.2 | 58.5 ± 6.1 | 0.56 |
RVSV (3D) | 68.3 ± 23.9 | 54.1 ± 18.8 | 68 ± 13.1 | 0.21 |
RVESV (3D) | 43.4 ± 22.5 | 34.7 ± 11.7 | 48.5 ± 11.6 | 0.34Ɨ |
RVEDV (3D) | 111.7 ± 42.8 | 88.8 ± 26.1 | 116.5 ± 19.8 | 0.18φ |
MVP Type | ||||
Posterior leaflet prolapse | 17 | 9 | 17 | |
Anterior leaflet prolapse | 2 | 1 | 1 |